Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma
Joffroy Rogier, Lucie Charon, Anne Durlach, Maxime Dewolf, Laëtitia Mokri, Antoine Braconier, Gaëtan Deslee, Julien Ancel · 2026
Read Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma by Joffroy Rogier, Lucie Charon, Anne Durlach, Maxime Dewolf, Laëtitia Mokri, Antoine Braconier, Gaëtan Deslee, Julien Ancel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263858.txt.
Description
Joffroy Rogier and co-authors report a hard treatment choice: giving immune-boosting cancer therapy to a kidney transplant patient with lung cancer. Checkpoint inhibitor drugs have improved outcomes in locally advanced lung cancer and now anchor standard care. Transplant patients were excluded from the trials, though, because the same immune boost can trigger organ rejection. Reported rejection rates in kidney recipients run from 25 to 45 percent, often with permanent graft loss.
The patient, a 69-year-old man transplanted in 2012, shows two lung masses that prove to be squamous cell cancer at stage IIIA. After joint discussion between cancer and kidney teams, he receives chemotherapy plus the inhibitor nivolumab before surgery. He tolerates it well with no kidney harm. Scans show clear tumor shrinkage, and surgeons remove the left lung. The authors present the case as a guide to balancing cancer control against graft safety.
Catalog record
| CREATOR | Joffroy Rogier, Lucie Charon, Anne Durlach, Maxime Dewolf, Laëtitia Mokri, Antoine Braconier, Gaëtan Deslee, Julien Ancel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |